Eli Lilly's obesity drug Zepbound demonstrated greater effectiveness compared to Novo Nordiskâs Wegovy in a recent clinical trial, achieving superior weight loss and waist circumference reductions. Conducted over 72 weeks, the study found an average waist loss of approximately 18.4 centimeters for Zepbound patients, outpacing Wegovy's 13 centimeters by a margin of 47%. Experts suggest that waistline measurements are crucial due to their link to dangerous abdominal fat, which is associated with various health risks, including heart disease and diabetes. The results could impact future prescribing habits in obesity treatment.
In the first head-to-head study, Lilly's Zepbound outperformed Novo's Wegovy, resulting in 47% more weight loss and about two inches less waist circumference after 72 weeks.
The significance of waist circumference reductions is profound, as a mere five-centimeter change can notably reduce blood pressure and improve metabolic health.
Research indicates that excess abdominal fat increases the risk of numerous diseases, highlighting the importance of medications that effectively target this fat.
Lilly's research may influence prescribing decisions, especially with the findings indicating a substantial reduction in waist size linked to cardiovascular health improvements.
Collection
[
|
...
]